1. Opening Hook
Bharat Parenterals decided to shut a plant for upgrades, slash revenue, and still walk into the concall smiling.
Q2 FY26 looked ugly on the topline, but management insists this was “planned pain,” not an accident.
Revenue collapsed, EBITDA barely showed up, and yet gross margins suddenly behaved like a specialty pharma company.
Meanwhile, the real drama happened off the P&L—Innoxel got its long-awaited USFDA approval.
So yes, the quarter hurt.
But apparently, this suffering is “investment for FY27 glory.”
Read on. The numbers say one thing, management says another, and the truth is sitting somewhere in H2 😏
2. At a Glance
- Standalone revenue ₹41.7 cr – Production shut, dispatches delayed, excuses fully loaded.
- Gross margin 44.1% – Revenue fell, margins hit the gym.
- EBITDA ₹2.3 cr (5.6%) – Thin, but still alive.
- PAT ₹2.7 cr – Barely breathing, but breathing.
- Consolidated EBITDA ₹0.8 cr – From loss to profit, baby steps.
- Innoxel USFDA approval – The real headline nobody waited 3 years for calmly.
3. Management’s Key Commentary
“This quarter was one of strategic execution and operational upgrades.”
(Translation: We broke revenue to fix the future 😏)
“The decline was anticipated due to a planned one-month production break.”
(Translation: Yes, we chose this pain)
“Gross margins expanded sharply to 44.1%.”
(Translation: At least something worked)
“Despite lower throughput, we remain firmly profitable.”
(Translation: Please ignore the revenue chart)
“Innoxel received USFDA EIR approval.”
(Translation: Finally. Finally. FINALLY.) 🎯
“Innoxel pipeline includes ~20 active products.”
(Translation: We’re not a one-drug miracle)
“We maintain
